FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $40.74, for a total transaction of $81,480.00. Following the sale, the director now directly owns 30,000 shares of the company’s stock, valued at $1,222,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Monday, September 18th, Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock. The stock was sold at an average price of $46.65, for a total transaction of $186,600.00.
  • On Monday, July 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $33.45, for a total transaction of $66,900.00.

Shares of FibroGen, Inc (NASDAQ:FGEN) opened at 51.35 on Friday. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $53.80. The company’s market capitalization is $3.66 billion. The stock’s 50 day moving average is $44.39 and its 200 day moving average is $32.56.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). The business had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts expect that FibroGen, Inc will post ($1.80) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/23/insider-selling-fibrogen-inc-fgen-director-sells-81480-00-in-stock.html.

Several equities research analysts have recently commented on the stock. Stifel Nicolaus reissued a “buy” rating and set a $80.00 target price on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC reissued a “buy” rating and set a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Leerink Swann reissued an “outperform” rating and set a $82.00 target price (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Finally, Citigroup Inc. boosted their target price on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. FibroGen presently has an average rating of “Buy” and a consensus target price of $60.17.

Several institutional investors have recently modified their holdings of FGEN. BlackRock Inc. increased its stake in shares of FibroGen by 29,724.1% in the 1st quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after acquiring an additional 4,439,882 shares in the last quarter. FMR LLC increased its stake in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. EcoR1 Capital LLC increased its stake in FibroGen by 3,674.1% during the 2nd quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after purchasing an additional 1,543,448 shares in the last quarter. Janus Henderson Group PLC bought a new stake in FibroGen during the 2nd quarter valued at about $45,633,000. Finally, Vanguard Group Inc. increased its stake in FibroGen by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after purchasing an additional 761,421 shares in the last quarter. Institutional investors own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.